Comparative Pharmacology
Head-to-head clinical analysis: ALMOTRIPTAN MALATE versus MAXALT MLT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALMOTRIPTAN MALATE versus MAXALT MLT.
ALMOTRIPTAN MALATE vs MAXALT-MLT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; cranial vasoconstriction and inhibition of trigeminal nerve transmission.
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial arteries and inhibits trigeminal nerve activation.
12.5 mg orally at onset of migraine; may repeat after 2 hours if headache recurs. Maximum 25 mg/day.
10 mg orally as a single dose; maximum 30 mg in 24 hours. Administer at onset of migraine; do not use for prophylaxis.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours. In patients with hepatic impairment, half-life may be prolonged (up to 6-7 hours), necessitating dose adjustment.
Terminal elimination half-life of approximately 2-3 hours; clinical context: short half-life supports acute migraine treatment with rapid offset.
Approximately 70% renal excretion (40% unchanged, 30% as metabolites), 30% fecal/biliary elimination.
Primarily hepatic metabolism; ~14% excreted unchanged in urine, ~76% as metabolites in feces via bile, total renal excretion of parent and metabolites ~40%.
Category C
Category C
Antimigraine Agent
Antimigraine Agent